The Coronavirus Disease of 2019: Prevention, Management and Treatment Strategies
Journal of Advances in Biology & Biotechnology,
The recent COVID-19 pandemic caused by the novel coronavirus (SARS-CoV2) has taken the world by surprise since its outbreak in 2019, and as on February 2021, the world had experienced a total of 107,643,141 (one hundred and seven million, six hundred and forty-three thousand, one hundred and forty-one) confirmed infection cases and 2,358,244 (two million, three hundred and fifty-eight thousand, two hundred and forty-four) deaths world-wide. This virus, although less lethal than the previous human coronaviruses (SARS-CoV and MERS-CoV), is reported highly infectious and mutable. This has led to a concerted effort by numerous governments and private organisations to try and halt the spread of the virus through the development of highly effective therapeutic drugs or prophylactic therapy. There are various drugs, vaccines and other forms of therapies currently being developed all over the world, with some at various clinical trial stages, with only one (Remdesivir) being fully approved treatment of the COVID-19 disease. The latest breakthrough with Dexamethasone has currently revealed the efficacy of the drug in treating critically ill and even mechanically ventilated COVID-19 patients, and this has led to the approval of the drug by the United Kingdom and World Health Organization (WHO). The recent development of a protective SARS-CoV-2 vaccine has created hope for life and restoration of normalcy.
- Covid-19 vaccine
How to Cite
Chen Y, Liu O, Guo D. Emerging Coronaviruses: Genome, structure, replication and pathogenesis. Journal of Medical Virology. 2020;22:418-23.
Wu R, Wang L, Kuo HCD, Shannar A, Peter R, Chou PJ, et al. An update on current therapeutic drugs treating COVID-19. Current Pharmacology Repoort. 2020;15-20.
Muhammad AS, Suliman K, Abeer K, Nadia B, Rabeea S. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. Journal of Advanced Research. 2020;91-98.
Anderson KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV2. Nature Medicine. 2020; 450-52.
Fung TS, Liu DX. Human coronavirus: Host-pathogen interaction. Annual Review of Microbiology. 2019;529-557.
Coppola S, Cressoni M, Busana M, Rossi S, Chiumello D. Covid-19 does not lead to a “typical” acute respiratory distress syndrome. American Journal of Respiratory and Critical Care Medicine. 2020;10.
Xiong Y, Liu Y, Cao L, Wang D, Guo M, Jiang AO, et al. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. Emerging Microbes and Infections Journal. 2020; 1:761-770.
Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. Coronaviruses - drug discovries and therapeutic options. Nature Reviews Drug Discovery. 2016;327-347.
Avadheshkumar RH, Kirtikumar BC, Rahoul Z, Hemant K, Vivek BC. A review of pharmacology, mechanism of action, in-vitro activity and clinical use based on available case studies. Journal of Drug Delivery and Therapeutics. 2020;264-270.
Marcia F. FDA authorizes emergency use of remdesivir for COVID-19. Medscape; 2020. Available:https://www.medscape.com/viewarticle/929836. Accessed: 2 February 2021.
Holshue ML, De Bolt C, Lindquist S, Lofy KH, Wiseman J, Bruce H, et al. First case of 2019 novel Coronavirus in the United States. National Library of Medicine. 2020;250-253.
Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, et al. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. JAMA. 2020;1843-1844.
Grein J, Ohmagari N, Shin D, Diaz G, Asper E, Castagna A, et al. Compassionate use of remdesivir for patients with severe Covid-19. The New England Journal of Medicine. 2020;250.
Silva J, Mariz H, Rocha JL, Oliveira P, Dantas A, Duarte A. Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients. Clinics. 2013; 766-771.
Rynes R. Antimalarial drugs in the treatment of rheumatological diseases. Pub Med. 1997;799-805.
Ohkuma S, Chudzik J, Poole B. The effects of basic substances and acidic ionophores on the digestion of exogenous and endogenous proteins in mouse peritoneal macrophages. The Journal of Cell Biology. 1986;959-966.
Cao X. Immunopathology and its implications for therapy. Nat Rev Immunol. 2020;1-2.
Te Velthuis AJ, Van Den Worm SH, Sims AC, Baric RS, Van Hemert MJ. "Aartjan J. W. te Velthuis,Sjoerd H. E. van den Worm,Amy C. Sims,Ralph S. Baric,Eric J. Snijder," Plos Pathogens 2010;6.
Te Velthuis AJ, Van Den Worm SH, Sims AC, Baric RS, Snijder EJ. Zn2+ Inhibits Coronavirus and Arterivirus RNA Polymerase Activity In Vitro and Zinc Ionophores Block the Replication of These Viruses in Cell Culture. Plos Pathogens. 2010;I(1):51-57.
Tang et al. Hydroxychloroquine in patients with COVID-19: An open-label, randomized, controlled trial. MedRxiv; 2020.
Borba M, Almeida VF, Sampaio V, Alexandre M, Melo G, Brito M. Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety result of a randomized, double-blinded clinical study. MedRxiv. 2020;1.
USFDA. Coronavirus (COVID-19) update: FDA revokes emergency use authorization for chloroquine and hydroxychloroquine," USFDA. 2020;1.
FDA. US department of health and human services; 2019. Available:https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021251s058.
Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. Ritonavir in adults hospitalized with Severe Covid-19. New England Journal of Medicine. 2020;120-127.
NIH. Antiviral drugs that are under evaluation for the treatment of COVID-19. Covid-19 Treatment Guideline. 2020;5.
Gunn BM, Yu WH, Karim MM, Brannan JM, Herbert AS. A role for Fc function in therapeutic monoclonal antibody-mediated protection against Ebola virus. Cell Host Microbe. 2018;221-233.
Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020;141-149.
Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. PNAS. 2020;1.
Jaroslaw D. [UPDATED] therapies for COVID-19: What is in the pipeline?. DLA Piper. 2020;6.
NIH. NIH COVID-19 Treatment Guideline; 2020. [Online]. Available:https://www.covid19treatmentguidelines.nih.gov/immune-based-therapy/blood-derived-products/convalescent-plasma/. Accessed: 1 November 2020.
BBC, dexamethasone, remdesivir, Regeneron: Trump's Covid treatment explained. USA: BBC; 2020.
Regeneron pharmaceuticals. Evaluation of the efficacy and safety of sarilumab in hospitalized patients With COVID-19. US National Library of Medicine. 2020;19.
ClinicalTrials. US NAtional Library of Medicine; 2020. Available: https://clinicaltrials.gov/.
Fu B, Xiaoling, Wei, Haiming. Why tocilizumab could be an effective treatment for severe COVID-19. Journal of Transitional Medicine. 2020;125.
Chineese critical trial registry. Trial Research: CHICTR; 2020. [Online]. Available:http://www.chictr.org.cn/showprojen.aspx?proj=49409.
NIAID. Safety and immunogenicity study of 2019-nCoV vaccine (mRNA-1273) for prophylaxis of SARS-CoV-2 infection (COVID-19). US National Library of Medicine. 2020;1.
Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. An mRNA Vaccine against SARS-CoV-2 — Preliminary Report. The New England Journal of Medicine. 2020;1.
Smith TRF, Broderick KE. Immogenicity of DNA vaciine candidate for COVID-19. Nature. 2020;1.
University of Oxford. News and events: University of Oxford; 2020. Available:http://www.ox.ac.uk/news/2020-05-22-oxford-covid-19-vaccine-begin-phase-iiiii-human-trials#.
Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij Rammerstorfer S. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1/2, single-blind, randomised controlled trial. The Lancelet. 2020;467-478.
Oxford University. Press release: Oxford University breakthrough on global COVID-19 vaccine. University of Oxford, Oxford; 2020.
CNN. "Why Oxford's Covid-19 vaccine could do more for the world than other shots. CNN Health, USA; 2020.
Vaccine Info. Vaccines: Vaccine info; 2020. Available:https://www.precisionvaccinations.com/vaccines/bnt162-sars-cov-2-vaccine.
Walsh et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. The New England Journal of Medicine. 2020;3.
Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatullin AI, Shcheblyakov DV, Dzharullaeva AS. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: Two open, non-randomised phase 1/2 studies from Russia. The Lancet. 2020; 112-113.
CNBC. Russia approves second Covid-19 vaccine after preliminary trials. CNBC. 2020;5-6.
Shengli X, Kai D, Yuntao Z. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: Interim analysis of 2 randomized clinical trials. JAMA Network. 2020;951-960.
Bharat biotech, Bharat biotech home. Bharat Biotech; 2020. Available:https://www.bharatbiotech.com/blog/vaccines/covaxin-phase-2-study-results-phase-1-follow-up-data. Accessed: 10 February 2021]
Bharat biotech. COVAXIN Bharat Biotech; 2021. Available:https://www.bharatbiotech.com/covaxin.html. Accessed: 10 Frebruary 2021. BBC. BBC NEWS. BBC; 2021 Available:https://www.bbc.com/news/world-asia-india-55748124#:~:text=The%20homegrown%20government%2Dbacked%20vaccine,be%20injected%20into%20the%20body. Accessed: 10 February 2021.
University of Oxford. Dexamethasone reduces death in hospitalised patients with severe respiratory complications of COVID-19. University of Oxford News. 2020;1. WHO. News-Room: WHO; 2020. [Online]. Available:https://www.who.int/news-room/detail/16-06-2020-who-welcomes-preliminary-results-about-dexamethasone-use-in-treating-critically-ill-covid-19-patients.
Carr AC, Maggini S. Vitamin C and immune function. MDPI. 2017;1211.
Kim Y, Kim H, Bae S, Choi J, Lim SY, Lee N, et al. Vitamin C is an essential factor on the anti-viral immune responses through the production of interferon-alpha/beta at the initial stage of influenza A virus (H3N2) infection. Immune Network. 2013;70-74.
Van Gorkom G, Klein Wolterink R, Van Elssen C, Wieten L, Germeraad W, Bos G. Influence of vitamin c on lymphocytes: An overview. MDPI; 2018. New-York Post. New-York Post News; 2020. Available:https://nypost.com/2020/03/24/new-york-hospitals-treating-coronavirus-patients-with-vitamin-c/.
Retallack H, Di Lullo E, Arias C, Knopp K, Laurie M, Sandoval-Espinosa C et al. Zika virus cell tropism in the developing human brain and inhibition by azithromycin. PNAS. 2016;14408-14413.
Madrid P, Panchal R, Warren T, Shurtleff A, Endsley A, Green C, et al. Evaluation of ebola virus inhibitors for drug repurposing. ACS Publications. 2015;317-326.
Gautret P, Lagier J, Parola P, Hoang V, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial. Intrnational Journal of Antimicrobial Agents. 2020;1.
Molina J, Delaugerre C, Le Goff J, Mela-Lima B, Ponscarme D, Goldwirt L. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Médecine et Maladies Infectieuses. 2020;4:384.
Chen W, Lim C, Kang H, Liu J. Chinese herbal medicines for the treatment of type A H1N1 influenza: A systematic review of randomized controlled trials. PLOS ONE. 2011;1.
Ang L, Lee H, Choi J, Zhang J, Soo L. Herbal medicine and pattern identification for treating COVID-19: a rapid review of guidelines. Science Direct. 2020;407.
Zhou S, Li W, Ai Z, Wang L, Ba Y. Investigating mechanism of qingfei Dayuan granules for treatment of COVID-19 based on network pharmacology and molecular docking. Chin Tradit Herb Drugs. 2020;1.
Luo H, Tang Q, Shang Y, Liang S, Yang M, Robins N, et al. Can Chinese medicine be used for prevention of corona virus disease 2019 (COVID-19)? A review of historical classics, research evidence and current prevention programs. Chinese Journal of Integrative Medicine. 2020;243-250.
Yang Y, Islam M, Wang J, Li Y, Chen X. Traditional Chinese medicine in the treatment of patients infected with 2019-new coronavirus (SARS-CoV-2): A review and perspective. International Journal of Biological Sciences. 2020;1708-1717.
Alfa Shaban AR, "COVID-organic: Madagascar launches Africa's first cure for virus. Africanews; 2020. Seeberger PH. MPICI; 2020. Available:https://www.mpg.de/14663263/artemisia-annua-corona-virus.
Abstract View: 65 times
PDF Download: 43 times